XILIO THERAPEUTICS, INC.

Consensus Xilio Therapeutics, Inc.

Stocks

XLO

US98422T2096

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-20 EDT			5-day change	1st Jan Change
9.230 ^USD	-1.91%		+2.44%	+2.98%

08-12	Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index	CI

Evolution of the Average Target: Xilio Therapeutics, Inc.

Evolution of the Target Price: Xilio Therapeutics, Inc.

Changes in Analyst Recommendations: Xilio Therapeutics, Inc.

2b07f040849354.TRuZXtgI4MUpZ1yfyvihLvmO_SJuMyeo0yzMizpQQe8.dVavGItYh7FGIT7wk8j1TarMyBFeQFDAvXOA504iMoEIV-gKgWHRjHkAEQ~a9af5390f4de8f8de7e09c370f6629f4

Analysts' recommendations: Xilio Therapeutics, Inc.

25-08-06	Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target	MT
23-01-27	Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating	MT
22-12-21	Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target	MT
22-11-10	Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating	MT
22-08-10	Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating	MT
22-01-10	HC Wainwright Starts Xilio Therapeutics at Buy with $36 Price Target	MT
21-11-16	Guggenheim Starts Xilio Therapeutics at Buy With $40 Price Target	MT
21-11-16	Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target	MT
21-11-16	Morgan Stanley Starts Xilio Therapeutics at Overweight With $32 Price Target	MT
21-11-16	Cowen Starts Xilio Therapeutics at Outperform	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XILIO THERAPEUTICS, INC.			-	-	+116.68%
	LONZA GROUP AG					+16.27%
	REVOLUTION MEDICINES, INC.					+5.43%
	BEONE MEDICINES AG					+17.3%
	IQVIA HOLDINGS INC.					+7.47%
	CELLTRION, INC.					+37.06%
	ASCENDIS PHARMA A/S					+22.78%
	MEDPACE HOLDINGS, INC.					-5.03%
	EUROFINS SCIENTIFIC SE					-0.4%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.59%
	Average					+21.40%
	Weighted average by Cap.					+12.90%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

9.230USD

Average target price

20.00USD

Spread / Average Target

+116.68%

High Price Target

20.00USD

Spread / Highest target

+116.68%

Low Price Target

20.00USD

Spread / Lowest Target

+116.68%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Leerink Partners
Morgan Stanley
Chardan Research
Raymond James
HC Wainwright
Cowen
Guggenheim

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

9.230USD

Average target price

20.00USD

Spread / Average Target

+116.68%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
XLO Stock
Consensus Xilio Therapeutics, Inc.

As early as today, start finding the best investment opportunities!